CDK4/6 inhibitors in breast cancer
Publication digest
View our publication digests to learn key findings on the use of CDK4/6 inhibitors for treatment of HR+/HER2−, node-positive, high-risk early breast cancer.
- Review data comparing clinical outcomes for various CDK4/6 inhibitors
- Learn the long-term benefits of adjuvant abemaciclib combined with endocrine therapy
- Consider the safety and tolerability profile of this combination therapy for breast cancer
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event